Vantis Vascular’s CrossFast System Used in First Commercial Cases

January 23, 2025—Vantis Vascular, Inc. announced the first commercial use of its CrossFast integrated microcatheter advanced delivery system in a series of 10 complex high-risk coronary interventional procedures (CHiP).

The CrossFast device is commercially available in the United States as part of a limited-market release. The full-market release is planned for later in 2025, as advised by the company.

According to the company, results from the initial clinical use of the CrossFast system demonstrated 100% procedural success with quick and reliable delivery to the target location, successful stent delivery, and no device-related complications.

Superior deliverability was noted during several highly complex cases where a traditional guide extension catheter failed to reach the target lesion and was swapped out for the CrossFast system, which was delivered with ease, reported Vantis Vascular.

The first commercial case was performed by Amir Kaki, MD, at St. John’s Hospital in Detroit, Michigan.

“CHiP procedures often involve patients with multiple comorbidities, tortuous anatomy, and significant disease, requiring specialized tools to deliver percutaneous therapies,” commented Dr. Kaki in the company’s press release. “The CrossFast advanced delivery system performed exceptionally well due to its ability to safely and efficiently navigate tight, highly calcified vessels. Despite the challenging anatomy, CrossFast was easily advanced, enabling stent delivery to the lesion which otherwise would have been difficult and time-consuming.

“This advanced delivery system is a whole new class of device that exceeds the performance of traditional guide extensions making this a welcomed tool in the complex operator’s toolbox.”